# A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Source: https://onco.cc/trials/nct06423170/  
OnCo record `nct06423170` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab, gemcitabine and oxaliplatin in gallbladder cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.

## Summary

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs is a phase 2 interventional study registered as NCT06423170 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 37 participants, started 2023-06-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: Camrelizumab plus GEMOX. Conditions listed: Unresectable Gallbladder Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06423170
- Phase: 2
- Setting: Camrelizumab Plus Gemcitabine and Oxaliplatin (GEMOX) in Patients for Unresectable Gallbladder Cancer: a Single-arm, Phase II Trial
- Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT06423170: https://clinicaltrials.gov/study/NCT06423170

## Connected records

- cancers: [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06423170.json